1. Döhner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute Myeloid Leukemia. N. Engl. J. Med. 373, 1136–1152 (2015).
2. Bhatia, M., Wang, J. C. Y., Kapp, U., Bonnet, D. & Dick, J. E. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc. Natl. Acad. Sci. 94, 5320–5325 (1997).
3. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).
4. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).
5. Bjerkvig, R., Tysnes, B. B., Aboody, K. S., Najbauer, J. & Terzis, A. J. A. The origin of the cancer stem cell: current controversies and new insights. Nat. Rev. Cancer 5, 899–904 (2005).
6. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105–111 (2001).
7. Tallman, M. S., Gilliland, D. G. & Rowe, J. M. Drug therapy for acute myeloid leukemia. Blood 106, 1154–1163 (2005).
8. Ng, S. W. K. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433–437 (2016).
9. Yilmaz, Ö. H. & Morrison, S. J. The PI-3kinase pathway in hematopoietic stem cells and leukemia-initiating cells: a mechanistic difference between normal and cancer stem cells. Blood Cells. Mol. Dis. 41, 73–76 (2008).
10. Wang, E. T. et al. Alternative Isoform Regulation in Human Tissue Transcriptomes. Nature 456, 470–476 (2008).
11. Black, D. L. Mechanisms of Alternative Pre-Messenger RNA Splicing. Annu. Rev. Biochem. 72, 291–336 (2003).
12. Chen, M. & Manley, J. L. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 10, 741–754 (2009).
13. Oltean, S. & Bates, D. O. Hallmarks of alternative splicing in cancer. Oncogene 33, 5311–5318 (2014).
14. Adamia, S. et al. A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 20, 1135–1145 (2014).
15. Crews, L. A. et al. RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell 19, 599–612 (2016).
16. Abrahamsson, A. E. et al. Glycogen synthase kinase 3 missplicing contributes to leukemia stem cell generation. Proc. Natl. Acad. Sci. 106, 3925–3929 (2009).
17. Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526–531 (2018).
18. Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N. Engl. J. Med. 374, 2209–2221 (2016).
19. The Cancer Genome Atlas Research Network. Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).
20. Wang, E. et al. Targeting an RNA-Binding Protein Network in Acute Myeloid Leukemia. Cancer Cell 35, 369-384.e7 (2019).
21. Ge, Y. et al. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia. Nat. Commun. 10, 172 (2019).
22. Ashburner, M. et al. Gene Ontology: tool for the unification of biology. Nat. Genet. 25, 25–29 (2000).
23. Shastri, A. et al. Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells. J. Clin. Invest. 128, 5479–5488 (2018).
24. Lechman, E. R. et al. miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells. Cancer Cell 29, 214–228 (2016).
25. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature 489, 57–74 (2012).
26. Supek, F., Bošnjak, M., Škunca, N. & Šmuc, T. REVIGO Summarizes and Visualizes Long Lists of Gene Ontology Terms. PLoS ONE 6, e21800 (2011).
27. Anande, G. et al. RNA Splicing Alterations Induce a Cellular Stress Response Associated with Poor Prognosis in Acute Myeloid Leukemia. Clin. Cancer Res. 26, 3597–3607 (2020).
28. De Maio, A. et al. RBM17 Interacts with U2SURP and CHERP to Regulate Expression and Splicing of RNA-Processing Proteins. Cell Rep. 25, 726-736.e7 (2018).
29. Khan, S. N. et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 27, 1301–1309 (2013).
30. van Vlerken, L. E. et al. EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl. Med. 2, 43–52 (2013).
31. Lim, K. M., Yeo, W. S. & Chow, V. T. K. Antisense abrogation of DENN expression induces apoptosis of leukemia cells in vitro, causes tumor regression in vivo and alters the transcription of genes involved in apoptosis and the cell cycle. Int. J. Cancer 109, 24–37 (2004).
32. Ji, D. et al. Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34 + cells via pre-B-cell leukemia homeobox 1. Oncogene 39, 443–453 (2020).
33. Ni, J. Z. et al. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev. 21, 708–718 (2007).
34. Hussain, T. et al. Structural changes enable start codon recognition by the eukaryotic translation initiation complex. Cell 159, 597–607 (2014).
35. Rapin, N. et al. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood 123, 894–904 (2014).
36. Lallena, M. J., Chalmers, K. J., Llamazares, S., Lamond, A. I. & Valcárcel, J. Splicing regulation at the second catalytic step by Sex-lethal involves 3’ splice site recognition by SPF45. Cell 109, 285–296 (2002).
37. Al-Ayoubi, A. M., Zheng, H., Liu, Y., Bai, T. & Eblen, S. T. Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion. Mol. Cell. Biol. 32, 2880–2893 (2012).
38. Perry, W. L. et al. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 65, 6593–6600 (2005).
39. Sampath, J. et al. Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells. Am. J. Pathol. 163, 1781–1790 (2003).
40. Lu, Y. et al. Alternative Splicing of MBD2 Supports Self-Renewal in Human Pluripotent Stem Cells. Cell Stem Cell 15, 92–101 (2014).
41. Tan, Q. et al. Extensive cryptic splicing upon loss of RBM17 and TDP43 in neurodegeneration models. Hum. Mol. Genet. 25, 5083–5093 (2016).
42. Sorek, R. The birth of new exons: Mechanisms and evolutionary consequences. RNA 13, 1603–1608 (2007).
43. Sorek, R., Shamir, R. & Ast, G. How prevalent is functional alternative splicing in the human genome? Trends Genet. TIG 20, 68–71 (2004).
44. Tanaka, S. et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120, 1107–1117 (2012).
45. Sadlish, H. et al. Evidence for a functionally relevant rocaglamide binding site on the eIF4A:RNA complex. ACS Chem. Biol. 8, 1519–1527 (2013).
46. Callahan, K. P. et al. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. Leukemia 28, 1960–1968 (2014).
47. Wilczynska, A. et al. eIF4A2 drives repression of translation at initiation by Ccr4-Not through purine-rich motifs in the 5′UTR. Genome Biol. 20, 262 (2019).
48. Stevens, B. M. et al. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. Nat. Commun. 9, 3694 (2018).
49. Majeti, R. et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proc. Natl. Acad. Sci. 106, 3396–3401 (2009).
50. Raffel, S. et al. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation. Nature 551, 384–388 (2017).
51. Kwan, V. et al. Proteomic Analysis Reveals Autism-Associated Gene DIXDC1 Regulates Proteins Associated with Mitochondrial Organization and Function. J. Proteome Res. 20, 1052–1062 (2021).
52. Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442–D450 (2019).
53. Karolchik, D. et al. The UCSC Genome Browser Database. Nucleic Acids Res. 31, 51–54 (2003).